<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human pancreatic growth hormone releasing factor [GRF(1-44)] is the largest molecule of several <z:chebi fb="7" ids="16670">peptides</z:chebi> recently isolated from <z:e sem="disease" ids="C0030297" disease_type="Neoplastic Process" abbrv="">pancreatic tumours</z:e> associated with <z:hpo ids='HP_0000845'>acromegaly</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It has been shown to stimulate the release of growth hormone in <z:mpath ids='MPATH_458'>normal</z:mpath> subjects and provides a safe and reliable tool for examining growth hormone release </plain></SENT>
<SENT sid="2" pm="."><plain>A study was conducted to examine the release of growth hormone in patients with Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>GRF(1-44) stimulated the release of growth hormone in <z:mpath ids='MPATH_458'>normal</z:mpath> subjects and produced no side effects </plain></SENT>
<SENT sid="4" pm="."><plain>A response of similar magnitude occurred in Type 1 diabetic patients despite their concomitant <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, the response in Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> was significantly impaired compared with <z:mpath ids='MPATH_458'>normal</z:mpath> volunteers (p less than 0.05) and Type 1 diabetic patients (p less than 0.02) </plain></SENT>
<SENT sid="6" pm="."><plain>These findings may well indicate that there is a defect in central hormonal control in Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>